News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

InterMune, Inc. (ITMN) To Release First Quarter Financial Results On May 1

4/23/2014 6:38:14 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

BRISBANE, Calif., April 23, 2014 /PRNewswire/ -- InterMune, Inc. (NASDAQ: ITMN) today announced that it will release its first quarter 2014 financial results at the close of the U.S. markets on Thursday, May 1, 2014. A live conference call and webcast will be hosted by InterMune at 4:30 p.m. Eastern time that same day.

InterMune logo.

Interested investors and others may participate in the conference call by dialing 800-745-9476 (U.S.) or +1 212-231-2906 (international), conference ID#21714990. A replay of the webcast and teleconference will be available on the company's website approximately three hours after the call. To access the live webcast, please log on to the company's website at at least 15 minutes prior to the start of the call to ensure adequate time for any software downloads that may be required.

A telephonic replay will be available for 10 business days following the call and can be accessed by dialing 800-633-8284 (U.S.) or +1 402-977-9140 (international), and entering the conference ID#21714990.

About InterMune
InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and orphan fibrotic diseases. In pulmonology, InterMune is focused on therapies for the treatment of idiopathic pulmonary fibrosis (IPF), a progressive and fatal lung disease. Pirfenidone is approved for marketing by InterMune in the EU and Canada as Esbriet®. Pirfenidone is not approved for marketing in the United States. InterMune intends to resubmit the pirfenidone New Drug Application (NDA) to the U.S. FDA early in the third quarter of 2014 to support regulatory registration in the United States. InterMune's research programs are focused on the discovery of targeted, small-molecule therapeutics and biomarkers to treat and monitor serious pulmonary and fibrotic diseases. For additional information about InterMune and its R&D pipeline, please visit

Logo -

SOURCE InterMune, Inc.

Help employers find you! Check out all the jobs and post your resume.

Read at

comments powered by Disqus